FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPR | OVAL |
|--------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average | burden |
| hours per response | e 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Typ | e Responses |) | | | | | | | | | | | |
|--|--------------|--|---|---|-------------|---|---|---|--|--|-------------------|---------------|--|
| Name and Address of Reporting Person * Saks Samuel R | | | | Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | |
| (Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306 | | | | 3. Date of Earliest 7 02/25/2016 | Transaction | (Moi | nth/Day/Y | ear) | Officer (give title below) | Other (specify | below) | | |
| (Street) NEW YORK, NY 10022 | | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person | | | |
| (City) |) | (State) | (Zip) | Ta | ble I - Non | -Der | ivative Se | curities | Acqu | ired, Disposed of, or Beneficial | ly Owned | | |
| 1.Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | Form: Direct (D | , | | |
| | | | | | Code | V | Amount | (A) or (D) | Price | | (I) (Instr. 4) | (Instr. 4) | |
| Common | Stock, \$0.0 | 01 par value | 05/27/2017 | | M | | 750 (1) | A | \$ 0 | 6,605 | D | | |
| Common | Stock, \$0.0 | 01 par value | 02/09/2017 | | M | | 750 <u>(1)</u> | A | \$ 0 | 5,855 | D | | |
| Common | Stock, \$0.0 | 01 par value | 02/25/2016 | | M | | 600 (1) | A | \$ 0 | 3,855 | D | | |
| | | | Table II - 1 | ies beneficially own Derivative Securition | es Acquirec | Personta conta orm l, Dis | ons who ained in displays sposed of convertil | this for s a curr , or Ben ble secur | m are ently eficial rities) | | lless the | C 1474 (9-02) | |
| 1. Title of | 2. | Transaction | 3A. Deemed | 4. 5. | Number 6. | Date | Exercisa | ble ' | 7. Title | e and 8. Price of 9. Nun | iber of 10. | 11. Natu | |

| I | Derivative Security Instr. 3) | Conversion | 3. Transaction Date (Month/Day/Year) | Execution Date, if | Code | tion) | of Deri Secu Acqu (A) o | vative arities uired or oosed O) cr. 3, | 6. Date Exer and Expirati (Month/Day | ion Date | Amount of Underlying | | Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | Ownership Form of Derivative Security: Direct (D) or Indirect | Beneficial Ownership (Instr. 4) |
|---|-------------------------------------|------------|--|--------------------|------|-----------|-------------------------------------|---|--|--------------------|-------------------------|--|--------------------------------------|--|--|---------------------------------------|
| | | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| 5 | Restricted Stock Jnits | (1) | 05/27/2017 | | M | | | 750 | <u>(2)</u> | <u>(2)</u> | Common Stock | 750 | \$ 0 | 0 | D | |
| 5 | Restricted Stock Jnits | (1) | 02/09/2017 | | M | | | 750 | (3) | (3) | Common Stock | 750 | \$ 0 | 0 | D | |
| 5 | Restricted Stock Jnits | <u>(1)</u> | 02/25/2016 | | M | | | 650 | <u>(4)</u> | <u>(4)</u> | Common Stock | 600 | \$ 0 | 0 | D | |

Reporting Owners

| D (O N / 111 | Relationships | | | | | | | |
|---|---------------|-----------|---------|-------|--|--|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | | |
| Saks Samuel R C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022 | X | | | | | | | |

Signatures

| / | /s/Jessica Morris, Attorney-in-Fact | 03/09/2018 |
|---|-------------------------------------|------------|
| | **Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock units convert into common stock on a one-for-one basis.
- (2) On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date.
- (3) On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date.
- (4) On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.